We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Protherics (MM) | NASDAQ:PTIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.30 | 0 | 01:00:00 |
Protherics PLC Rule 2.10 announcement Not for release, publication or distribution (in whole or in part) in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. London, UK; Brentwood, TN, US: 10 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the "Code"), confirms that as at the close of business on 9 October 2008, the Company has 342,560,165 ordinary shares of 2 pence each in issue and admitted to trading on the London Stock Exchange under the UK ISIN Code GB0007029209. / Ends / For further information please contact: Protherics Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510 Julie Vickers, Company Secretary +44 (0)1928 518010 Jefferies International Limited (Financial +44 (0) 20 7029 8292 Adviser) Ian Crosbie, Director Nomura Code Securities Limited (Corporate Broker) +44 (0) 20 7776 1203 Phil Walker, Director Financial Dynamics - press enquiries London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113 New York: John Capodanno +1 212 850 5600 Or visit www.protherics.com Dealing Disclosure Requirements Under the provisions of Rule 8.3 of the Code, if any person is, or becomes "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Protherics, all "dealings" in any relevant securities" of Protherics (including by means of an option in respect of, or a derivative references to, any such "relevant securities") must be publicly disclosed by no later than 3.30pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in"relevant securities" of Protherics they will be deemed to a single person for the purpose of Rule 8.3. Under the provisions of Rule 8.1 of the Code, all "dealings" in"relevant securities" of Protherics by the potential offeror, or by Protherics, or by any of their respective "associates", must be disclosed by no later than 12.00 noon (London time) on the business day following the date of the relevant transaction. A disclosure table, giving details of the companies in whose "relevant securities""dealings" should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.takeoverpanel.org.uk.'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. Terms in quotation marks are defined in the Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a 'dealing' under Rule 8, you should consult the Panel. This information is provided by RNS The company news service from the London Stock Exchange END
Contacts: RNS Customer Services 0044-207797-4400 Email Contact http://www.rns.com
1 Year Protherics Chart |
1 Month Protherics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions